CRISPR Therapeutics AG (CRSP) Analysts See $-0.65 EPS as of May, 10

April 17, 2018 - By Sonya McDaniel

On May, 10. Investors wait CRISPR Therapeutics AG (NASDAQ:CRSP) to publish its quarterly earnings, as reported by RTT. This year’s EPS analyst estimate is awaited to be $-0.65. That is 20.37 % down compareed to $-0.54 EPS for last year. The stock decreased 1.14% or $0.59 during the last trading session, reaching $51.18.Currently CRISPR Therapeutics AG is uptrending after 144.93% change in last April 17, 2017. CRSP has also 1.03 million shares volume. The stock outperformed the S&P 500 by 133.38%.

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene medicines for the treatment of serious human diseases using its proprietary clustered, regularly interspaced short palindromic repeats associated protein-9 gene-editing platform in Switzerland.The firm is worth $2.41 billion. The CRISPR/Cas9 technology allows for changes to genomic DNA.Currently it has negative earnings. It has a collaboration agreement with Vertex Pharmaceuticals, Incorporated to develop, manufacture, commercialize, sell, and use therapeutics; a license agreement with Anagenesis Biotechnologies SAS; and a service agreement with MaSTherCell SA to develop and manufacture allogeneic CAR-T therapies.

CRISPR Therapeutics AG (NASDAQ:CRSP) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.